Monday, March 27, 2017
 
 
Company News: Page (1) of 1 - 01/11/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
World Multiple Myeloma Drugs Market (9.19% CAGR) to 2021
ReportsnReports.com adds Global Multiple Myeloma Drugs Market 2017-2021 latest research report, the analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the per... By PR Newswire

PUNE, India, Jan. 11, 2017 /PRNewswire-iReach/ -- The global multiple myeloma drugs market analyst says the latest trend gaining momentum in the market is emergence of nanomedicine platform. The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor.

Complete report on multiple myeloma drugs market spread across 86 pages, analyzing 5 major companies and providing 56 data exhibits is now available at http://www.reportsnreports.com/reports/799226-global-multiple-myeloma-drugs-market-2017-2021.html

The following companies are the key players in the global multiple myeloma drugs market: Amgen, Celgene, Johnson & Johnson, Novartis, and Takeda Pharmaceuticals. Other prominent vendors in the market are: AB Science, AbbVie, Acceleron Pharma, Acetylon Pharmaceuticals, Adaptimmune Therapeutics, Alexion Pharmaceuticals, AmpliMed Corporation, Array BioPharma, Benovus Bio, BioInvent, Biokine Therapeutics, Biotest, bluebird bio, Bristol-Meyer Squibb, Calithera Biosciences, CASI Pharmaceuticals, Celldex Therapeutics, Cellectar Biosciences, Chroma Therapeutics, Cleave Biosciences, Curis, Dicerna Pharmaceuticals, Eureka Therapeutics, F. Hoffmann-La Roche, Geron Corporation, GlycoMimetics, GlaxoSmithKline, ImmunoGen, Immunomedics, Innate Pharma, JW Pharmaceutical, Karyopharm Therapeutics, Kyowa Hakko Kirin, Merck, Midatech Pharma, Mirna Therapeutics, Molecular Partners, MorphoSys, NOXXON Pharma, Oncoceutics, Oncolytics Biotech, OncoPep, Oncopeptides, Ono Pharmaceutical, Otsuka Pharmaceuticals, Patrys, PharmaMar, Polyphor, Prothena Therapeutics, Sanofi, Sevion Therapeutics, Specialised Therapeutics, Spectrum Pharmaceutical, SymBio Pharmaceuticals, TaiGen Biotechnology, Tragara Pharmaceuticals, Vaxil Therapeutics, and Vivolux. Order a copy of Global Multiple Myeloma Drugs Market 2017-2021 report @ http://www.reportsnreports.com/purchase.aspx?name=799226


According to the multiple myeloma drugs market report, one of the major drivers for this market is growing demand for biologic therapies. The market has been witnessing a growing demand for biologic therapies, which is expected to drive market growth. Biologic therapy is a treatment that triggers the body's immune system to fight myeloma cells. Biologic therapies boost the immune system cells that identify and attack cancer cells. The demand for targeted therapies is due to its higher efficacy than other conventional therapies, which involves in destroying healthy cells too.

The top three revenue contributing therapy segments are discussed below:

Biologic therapy: Biological therapy drugs use the body's immune system to fight myeloma cells. The segment is expected to benefit from the increasing preference of physicians to adopt biologics owing to their established clinical profile. Targeted therapy: Targeted therapy focuses on specific abnormalities within cancer cells that enable to survive. Targeted therapies are mostly classified into proteasome inhibitors and histone deacetylase inhibitors. Chemotherapy: Chemotherapy drugs act by destroying fast-growing cells, including myeloma cells. These drugs can be given through intravenous or oral form.

Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, this report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

Further, the multiple myeloma drugs market report states that the growing popularity of CAM is expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking CAM therapies. The increased demand for these therapies is also due to the high cost of multiple myeloma therapeutics.

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE ReportsnReports

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


 







About Digital Facility - Contact Us - Advertise With Us - Privacy Guidelines